Norges Bank
ATXS

Norges Bank’s Astria Therapeutics ATXS Stock Holding History

Norges Bank’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,300
Closed -$269K – 1974
2023
Q2 		$269K Buy
+32,300
New +$373K ﹤0.01% 1986
2015
Q3 		– Sell
-667
Closed -$488K – 2286
2015
Q2 		$488K Buy
+667
New +$504K ﹤0.01% 2186

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Norges Bank's ATXS Position: Q3 2023 in Review

Norges Bank sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 32,300 shares — an estimated $269K sold.

Norges Bank first reported a position in ATXS in Q2 2015 and held it in 2 quarters. The position peaked at $488K in Q2 2015. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

  • Norges Bank reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Norges Bank sold 32,300 Astria Therapeutics shares in Q3 2023, an estimated $269K.
  • Norges Bank first reported a position in Astria Therapeutics in Q2 2015 and held it in 2 quarters.
  • Norges Bank's Astria Therapeutics position peaked at $488K in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.